ENGOT EN20

A RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL OF MAINTENANCE WITH SELINEXOR/ PLACEBO AFTER COMBINATION CHEMOTHERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Description: This placebo controlled, double-blind trial assesses the effectiveness of Selinexor as maintenance treatment in women with P53 wild type, advanced or recurrent endometrial cancer
Study Phase: Phase 3
Principal Investigator: Prof Karen Cadoo
Further information

MK-2870-005/ ENGOT-en23/GOG-3095

A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Sacituzumab Tirumotecan Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy
Description: Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare MK-2870 sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive MK-2870 sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy.
Study Phase: Phase 3
Principal Investigator: Prof Karen Cadoo
Further information

Enquire about a Cancer Clinical Trial

If you would like more information on Cancer Clinical Trials you can contact us.

Make an enquiry